Elanco Animal Health Incorporated Cost of Revenue
Elanco Animal Health Incorporated (ELAN) reported Cost of Revenue of $570.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-05
- Elanco Animal Health Incorporated cost of goods and services sold for the quarter ending 2026-06-30 was $570.00M, a 7.95% increase year-over-year.
- Elanco Animal Health Incorporated cost of goods and services sold for the quarter ending 2026-03-31 was $586.00M, a 15.13% increase year-over-year.
- Elanco Animal Health Incorporated cost of goods and services sold for the quarter ending 2025-12-31 was $555.00M, a 10.78% increase year-over-year.
- Elanco Animal Health Incorporated cost of goods and services sold for the quarter ending 2025-09-30 was $530.00M, a 7.72% increase year-over-year.
- Elanco Animal Health Incorporated cost of goods and services sold for fiscal 2025 was $2.12B, a 5.94% increase from fiscal 2024.
- Elanco Animal Health Incorporated cost of goods and services sold for fiscal 2024 was $2.00B, a 3.73% increase from fiscal 2023.
- Elanco Animal Health Incorporated cost of goods and services sold for fiscal 2023 was $1.93B, a 0.94% increase from fiscal 2022.
- Elanco Animal Health Incorporated cost of goods and services sold for fiscal 2022 was $1.91B, a 10.27% decline from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $570.00M 10-Q · filed 2026-08-05 | $1.16B 10-Q · filed 2026-08-05 | $1.71B derived: sum of 3 quarters · filed 2026-08-05 | $2.24B derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $586.00M 10-Q · filed 2026-05-06 | $1.14B derived: sum of 2 quarters · filed 2026-05-06 | $1.67B derived: sum of 3 quarters · filed 2026-05-06 | $2.20B derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $555.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.08B derived: sum of 2 quarters · filed 2026-02-24 | $1.61B derived: sum of 3 quarters · filed 2026-08-05 | $2.12B 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $530.00M 10-Q · filed 2025-11-05 | $1.06B derived: sum of 2 quarters · filed 2026-08-05 | $1.57B 10-Q · filed 2025-11-05 | $2.07B derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $528.00M 10-Q · filed 2026-08-05 | $1.04B 10-Q · filed 2026-08-05 | $1.54B derived: sum of 3 quarters · filed 2026-08-05 | $2.03B derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $509.00M 10-Q · filed 2026-05-06 | $1.01B derived: sum of 2 quarters · filed 2026-05-06 | $1.50B derived: sum of 3 quarters · filed 2026-05-06 | $2.00B derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $501.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $993.00M derived: sum of 2 quarters · filed 2026-02-24 | $1.49B derived: sum of 3 quarters · filed 2026-02-24 | $2.00B 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | $492.00M 10-Q · filed 2025-11-05 | $987.00M derived: sum of 2 quarters · filed 2025-11-05 | $1.50B 10-Q · filed 2025-11-05 | $2.02B derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-06-30 | $495.00M 10-Q · filed 2025-08-07 | $1.01B 10-Q · filed 2025-08-07 | $1.53B derived: sum of 3 quarters · filed 2026-02-24 | $2.01B derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-03-31 | $515.00M 10-Q · filed 2025-05-07 | $1.03B derived: sum of 2 quarters · filed 2026-02-24 | $1.52B derived: sum of 3 quarters · filed 2026-02-24 | $1.95B derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | $516.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.00B derived: sum of 2 quarters · filed 2026-02-24 | $1.44B derived: sum of 3 quarters · filed 2026-02-24 | $1.93B 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | $487.00M 10-Q · filed 2024-11-07 | $921.00M derived: sum of 2 quarters · filed 2024-11-07 | $1.42B 10-Q · filed 2024-11-07 | $1.86B derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-06-30 | $434.00M 10-Q · filed 2024-08-08 | $928.00M 10-Q · filed 2024-08-08 | $1.38B derived: sum of 3 quarters · filed 2025-02-25 | $1.85B derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-03-31 | $494.00M 10-Q · filed 2024-05-08 | $942.00M derived: sum of 2 quarters · filed 2025-02-25 | $1.41B derived: sum of 3 quarters · filed 2025-02-25 | $1.90B derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2022-12-31 | $448.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $920.00M derived: sum of 2 quarters · filed 2025-02-25 | $1.40B derived: sum of 3 quarters · filed 2025-02-25 | $1.91B 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | $472.00M 10-Q · filed 2023-11-07 | $956.00M derived: sum of 2 quarters · filed 2023-11-07 | $1.47B 10-Q · filed 2023-11-07 | $1.98B derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-06-30 | $484.00M 10-Q · filed 2023-08-07 | $993.00M 10-Q · filed 2023-08-07 | $1.50B derived: sum of 3 quarters · filed 2024-02-26 | $2.00B derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-03-31 | $509.00M 10-Q · filed 2023-05-09 | $1.02B derived: sum of 2 quarters · filed 2024-02-26 | $1.52B derived: sum of 3 quarters · filed 2024-02-26 | $2.07B derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2021-12-31 | $510.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $1.01B derived: sum of 2 quarters · filed 2024-02-26 | $1.56B derived: sum of 3 quarters · filed 2024-02-26 | $2.13B 10-K · filed 2024-02-26 | $2.13B 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $502.00M 10-Q · filed 2022-11-08 | $1.05B derived: sum of 2 quarters · filed 2023-03-01 | $1.62B 10-Q · filed 2022-11-08 | $2.22B derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-06-30 | $551.00M 10-K · filed 2023-03-01 | $1.12B 10-Q · filed 2022-08-08 | $1.71B derived: sum of 3 quarters · filed 2023-03-01 | $2.16B derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-03-31 | $566.00M 10-K · filed 2023-03-01 | $569.00M 10-Q · filed 2021-05-07 | $1.16B derived: sum of 2 quarters · filed 2023-03-01 | $1.60B derived: sum of 3 quarters · filed 2023-03-01 | $1.90B derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2020-12-31 | $596.20M 10-K · filed 2021-03-01 | $1.04B derived: sum of 2 quarters · filed 2021-11-05 | $1.33B derived: sum of 3 quarters · filed 2021-11-05 | $1.67B 10-K · filed 2023-03-01 | $1.67B 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $442.00M 10-Q · filed 2021-11-05 | $441.80M 10-Q · filed 2020-11-06 | $738.00M derived: sum of 2 quarters · filed 2021-11-05 | $1.07B 10-Q · filed 2021-11-05 | $1.07B 10-Q · filed 2020-11-06 | $1.48B derived: sum of 4 quarters · filed 2021-11-05 | ||
| 2020-06-30 | $296.00M 10-Q · filed 2021-08-09 | $295.90M 10-Q · filed 2020-07-30 | $629.00M 10-Q · filed 2021-08-09 | $628.60M 10-Q · filed 2020-07-30 | $1.04B derived: sum of 3 quarters · filed 2021-08-09 | $1.40B derived: sum of 4 quarters · filed 2021-08-09 | ||
| 2020-03-31 | $333.00M 10-Q · filed 2021-05-07 | $332.70M 10-Q · filed 2020-05-07 | $743.10M derived: sum of 2 quarters · filed 2021-05-07 | $1.10B derived: sum of 3 quarters · filed 2021-05-07 | $1.46B derived: sum of 4 quarters · filed 2021-05-07 | |||
| 2019-12-31 | $410.10M 10-K · filed 2021-03-01 | $770.50M derived: sum of 2 quarters · filed 2021-03-01 | $1.13B derived: sum of 3 quarters · filed 2021-03-01 | $1.47B 10-K · filed 2022-02-28 | $1.47B 10-K · filed 2020-02-28 | |||
| 2019-09-30 | $360.40M 10-Q · filed 2020-11-06 | $716.40M derived: sum of 2 quarters · filed 2020-11-06 | $1.06B 10-Q · filed 2020-11-06 | $1.47B derived: sum of 4 quarters · filed 2020-11-06 | ||||
| 2019-06-30 | $356.00M 10-Q · filed 2020-07-30 | $699.80M 10-Q · filed 2020-07-30 | $1.11B derived: sum of 3 quarters · filed 2020-07-30 | $1.48B derived: sum of 4 quarters · filed 2020-07-30 | ||||
| 2019-03-31 | $343.80M 10-Q · filed 2020-05-07 | $756.30M derived: sum of 2 quarters · filed 2020-05-07 | $1.13B derived: sum of 3 quarters · filed 2020-05-07 | $1.56B derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | $412.50M 10-K · filed 2020-02-28 | $782.30M derived: sum of 2 quarters · filed 2020-02-28 | $1.21B derived: sum of 3 quarters · filed 2020-02-28 | $1.57B 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $369.80M 10-K · filed 2020-02-28 | $801.30M derived: sum of 2 quarters · filed 2020-02-28 | $1.16B 10-Q · filed 2019-11-08 | $1.57B derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-06-30 | $431.50M 10-K · filed 2020-02-28 | $791.50M 10-Q · filed 2019-08-13 | $1.20B derived: sum of 3 quarters · filed 2020-02-28 | $1.57B derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-03-31 | $360.00M 10-K · filed 2020-02-28 | $765.00M derived: sum of 2 quarters · filed 2020-02-28 | $1.14B derived: sum of 3 quarters · filed 2020-02-28 | $1.52B derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2017-12-31 | $405.00M 10-K · filed 2019-02-20 | $781.20M derived: sum of 2 quarters · filed 2019-02-20 | $1.16B derived: sum of 3 quarters · filed 2019-02-20 | $1.49B 10-K · filed 2020-02-28 | ||||
| 2017-09-30 | $376.20M 10-K · filed 2019-02-20 | $750.20M derived: sum of 2 quarters · filed 2019-02-20 | $1.09B 10-Q · filed 2018-11-08 | |||||
| 2017-06-30 | $374.00M 10-K · filed 2019-02-20 | $712.60M derived: sum of 2 quarters · filed 2019-02-20 | ||||||
| 2017-03-31 | $338.60M 10-K · filed 2019-02-20 | |||||||
| 2016-12-31 | $1.41B 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |